MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling

Cancer Research

Volumn 72, Issue 7, 2012, Pages 1751-1762

  Zhang, Pingyu ^a   Bill, Katelynn ^a,b,d   Liu, Juehui ^a   Young, Eric ^a   Peng, Tingsheng ^a   Bolshakov, Svetlana ^a   Hoffman, Aviad ^a   Song, Yechun ^a   Demicco, Elizabeth G ^a   Terrada, Dolores Lopez ^b   Creighton, Chad J ^c   Anderson, Matthew L ^c   Lazar, Alexander J ^a,b,d   Calin, George G ^a   Pollock, Raphael E ^a   Lev, Dina ^a,b,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Dan L Luke Cancer Center   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASEIN KINASE IALPHA; CYCLIN D1; MICRORNA; MICRORNA 155; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER REGRESSION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSARCOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RNA ANALYSIS; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT;

ANIMALS; BASE SEQUENCE; BETA CATENIN; CASEIN KINASE I; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSARCOMA; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; ONCOGENES; SIGNAL TRANSDUCTION;

EID: 84859408905     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3027     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Fletcher CDM, Unni KK, Mertens F. Pathology and genetics of soft tissue and bone: World Health Organization Classification of Tumors. Genetics of Tumors of Soft Tissue and Bone IARC Press, Lyon, France 2002.
3. Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999;24:30-41. (Pubitemid 28544460)
4. Stojadinovic A, Leung DHY, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 2002;235:424-34. (Pubitemid 34183894)
5. Zagars GK, Ballo MT, Pisters PWT, Pollock RE, Patel SR, Benjamin RS. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer 2003;97:2544-53. (Pubitemid 36542494)
6. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003;238:358-71. (Pubitemid 38174479)
7. Evans HL, Soule EH, Winkelmann RK. Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma. A reappraisal of 30 cases formerly classified as well differentiated liposarcoma. Cancer 1979;43:574-84.
8. Fabre-Guillevin E, Coindre JM, De Saint Aubain Somerhausen N, Bonichon F, Stoeckle E, Bui NB. Retroperitoneal liposarcomas: Follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas. Cancer 2006;106:2725-33.
9. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5. (Pubitemid 39265675)
10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66. (Pubitemid 44629897)
11. Ugras S, Brill ER, Jacobsen A, Hafner M, Socci ND, Decarolis PL, et al. Small RNA sequencing and functional characterization reveals micro-RNA-143 tumor suppressor activity in liposarcoma. Cancer Res 2011;71:5659-69.
12. Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, Heinrich MC, et al. MicroRNA expression signature of human sarcomas. Oncogene 2008;27:2015-26. (Pubitemid 351442735)
13. Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, et al. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest 2011;91:392-403.
14. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. J Pathol 2009;218:292-300.
15. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 2009;249:1014-22.
16. Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009;15:3472-83.
17. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Meth 2007;4:721-6. (Pubitemid 47338166)
18. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, et al. MicroRNA-155 regulates cell survival, growth and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010;285:17869-79.
19. Zhang P, Yang Y, Nolo R, Zweidler-McKay PA, Hughes DPM. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex1 and its role in osteosarcoma invasiveness. Oncogene 2010;29:2916-26.
20. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89.
21. Habbe N, Koorstra J-BM, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009;8:340-6.
22. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005;102:3627-32. (Pubitemid 40354662)
23. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: A typical multifunctional microRNA. Biochimi Biophys Acta 2009;1792:497-505.
24. Jiang S, Zhang H-W, Lu M-H, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010;70:3119-27.
25. Megraw M, Sethupathy P, Corda B, Hatzigeorgiou AG. miRGen: A database for the study of animal microRNA genomic organization and function. Nucleic Acids Res 2006;35:D149-D155. (Pubitemid 46056188)
26. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, et al. Axin-mediated CKI phosphorylation of β-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 2002;16:1066-76. (Pubitemid 34507196)
27. MacDonald BT, Tamai K, He X. Wnt/β-Catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
28. Xiang X, Zhuang X, Ju S, Zhang S, Jiang H, Mu J, et al. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene 2011;30:3340-53.
29. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008;205:585-94. (Pubitemid 351439306)
30. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61. (Pubitemid 43271657)
31. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-8. (Pubitemid 351656494)
32. Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70. (Pubitemid 41161233)
33. Yan L-X, Huang X-F, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-60.
34. Wang X, Tang S, Le S-Y, Lu R, Rader JS, Meyers C, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008;3:e2557.
35. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;26:4442-52. (Pubitemid 47014466)
36. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98. (Pubitemid 43357945)
37. Greither T, Grochola LF, Udelnow A, Lautenschläger C, Würl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010;126:73-80.
38. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice. Proc Natl Acad Sci USA 2006;103:7024-9.
39. Georgantas RW, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S, et al. CD34 +hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007;104:2750-5. (Pubitemid 46327951)
40. Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eμ-MiR-155 transgenic mice. Blood 2009;114:1374-82.
41. Gironella M, Seux Mn, Xie M-J, Cano C, Tomasini R, Gommeaux J, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007;104:16170-5.
42. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008;28:6773-84.
43. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010;107:6982-7.
44. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50. (Pubitemid 40558990)
45. Vijayakumar S, Liu G, Rus Ioana A, Yao S, Chen Y, Akiri G, et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell 2011;19:601-12.
46. Sakamoto A, Oda Y, Adachi T, Saito T, Tamiya S, Iwamoto Y, et al. β-Catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma. Arch Pathol Lab Med 2002;126:1071-8. (Pubitemid 36221845)
47. Huart A-S, MacLaine NJ, Meek DW, Hupp TR. CK1α plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem 2009;284:32384-94.
48. Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Würl PU, et al. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie 2005;28:508-14. (Pubitemid 41420848)
49. Clinical trials [Internet]. Bethesda (MD): National Library of Medicine (US); 1993. [cited 2012 Jan 23]. Available from: http://clinicaltrials.gov
50. Onconova.com [Internet]. Newtown (PA): Onconova Therapeutics, Inc.; c2009 [cited 2012 Jan 23]. Available from: http://www.onconova.com/on013105.shtml